Combination treatment with doxorubicin and gamitrinib synergistically augments anticancer activity through enhanced activation of Bim
Open Access
- 13 June 2014
- journal article
- Published by Springer Nature in BMC Cancer
- Vol. 14 (1) , 431
Abstract
A common approach to cancer therapy in clinical practice is the combination of several drugs to boost the anticancer activity of available drugs while suppressing their unwanted side effects. In this regard, we examined the efficacy of combination treatment with the widely-used genotoxic drug doxorubicin and the mitochondriotoxic Hsp90 inhibitor gamitrinib to exploit disparate stress signaling pathways for cancer therapy.Keywords
This publication has 42 references indexed in Scilit:
- Resistance to paclitxel in breast carcinoma cells requires a quality control of mitochondrial antiapoptotic proteins by TRAP1Molecular Oncology, 2013
- Control of Tumor Bioenergetics and Survival Stress Signaling by Mitochondrial HSP90sCancer Cell, 2012
- Combinatorial drug therapy for cancer in the post-genomic eraNature Biotechnology, 2012
- Preclinical Characterization of Mitochondria-Targeted Small Molecule Hsp90 Inhibitors, Gamitrinibs, in Advanced Prostate CancerClinical Cancer Research, 2010
- Targeting the dynamic HSP90 complex in cancerNature Reviews Cancer, 2010
- DR5‐mediated DISC controls caspase‐8 cleavage and initiation of apoptosis in human glioblastomasJournal of Cellular and Molecular Medicine, 2010
- Different contribution of BH3-only proteins and caspases to doxorubicin-induced apoptosis in p53-deficient leukemia cellsBiochemical Pharmacology, 2010
- Multisite Phosphorylation Regulates Bim Stability and Apoptotic ActivityMolecular Cell, 2008
- Doxorubicin prevents endoplasmic reticulum stress-induced apoptosisBiochemical and Biophysical Research Communications, 2006
- Risk Factors for Doxorubicin-lnduced Congestive Heart FailureAnnals of Internal Medicine, 1979